Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2026 08:30 ET | Source: CorMedix, Inc.

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before...
April 27, 2026 07:30 ET | Source: CorMedix, Inc.

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for toxicity related...
April 07, 2026 08:30 ET | Source: CorMedix, Inc.

CorMedix to Participate in Needham Virtual Healthcare Conference

PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
March 05, 2026 07:30 ET | Source: CorMedix, Inc.

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call...
March 02, 2026 08:30 ET | Source: CorMedix, Inc.

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
February 12, 2026 08:30 ET | Source: CorMedix, Inc.

CorMedix to Participate in Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
February 02, 2026 08:30 ET | Source: CorMedix, Inc.

CorMedix Therapeutics Announces Share Repurchase Program

BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
January 29, 2026 08:30 ET | Source: CorMedix, Inc.

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
January 09, 2026 08:30 ET | Source: CorMedix, Inc.

CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
January 08, 2026 08:05 ET | Source: CorMedix, Inc.

CorMedix Therapeutics Announces Leadership and Board Updates

BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...